Pure Bioscience Inc (PURE) financial statements (2021 and earlier)

Company profile

Business Address 9669 HERMOSA AVENUE
RANCHO CUCAMONGA, CA 91730
State of Incorp. DE
Fiscal Year End July 31
SIC 289 - Miscellaneous Chemical Products (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2021
Q2
10/31/2020
Q1
7/31/2020
Q4
4/30/2020
Q3
1/31/2020
Q2
10/31/2019
Q1
7/31/2019
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3342010
Cash and cash equivalents3342010
Receivables0112000
Inventory, net of allowances, customer advances and progress billings1110000
Inventory1110000
Prepaid expense0000000
Other undisclosed current assets0000000
Total current assets:4564111
Noncurrent Assets
Property, plant and equipment1000000
Intangible assets, net (including goodwill)0000011
Intangible assets, net (excluding goodwill)0000011
Total noncurrent assets:1111111
TOTAL ASSETS:5665122
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1121111
Accounts payable1111111
Accrued liabilities0000000
Total current liabilities:1121111
Noncurrent Liabilities
Liabilities, other than long-term debt      0
Deferred rent credit      0
Total noncurrent liabilities:      0
Total liabilities:1121111
Stockholders' equity
Stockholders' equity attributable to parent5553111
Common stock1111111
Additional paid in capital128128127127125125124
Accumulated deficit(124)(124)(123)(125)(125)(125)(123)
Total stockholders' equity:5553111
TOTAL LIABILITIES AND EQUITY:5665122

Income statement (P&L) ($ in millions)

1/31/2021
Q2
10/31/2020
Q1
7/31/2020
Q4
4/30/2020
Q3
1/31/2020
Q2
10/31/2019
Q1
7/31/2019
Q4
Revenues1242001
Cost of revenue
(Cost of Goods and Services Sold)
(0)(1)(2)(1)(0)(0)(0)
Gross profit:1121000
Operating expenses(1)(1)0(2)(1)(2)(1)
Other undisclosed operating income (loss)  (1)1000
Operating income (loss):(1)(0)10(1)(1)(1)
Nonoperating income (expense)(0)(0)0(0)(0)00
Other nonoperating income (expense)    (0)00
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Net income (loss):(1)(0)10(1)(1)(1)
Other undisclosed net income (loss) attributable to parent00(0)0000
Net income (loss) available to common stockholders, diluted:(1)(0)10(1)(1)(1)

Comprehensive Income ($ in millions)

1/31/2021
Q2
10/31/2020
Q1
7/31/2020
Q4
4/30/2020
Q3
1/31/2020
Q2
10/31/2019
Q1
7/31/2019
Q4
Net income (loss):(1)(0)10(1)(1)(1)
Comprehensive income (loss), net of tax, attributable to parent:(1)(0)10(1)(1)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: